NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
RDGT
Ridgetech Inc.
There isn't enough reported data to score RDGT yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
RDGT Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Strong |
RDGT's profitability and balance sheet are currently healthy. There isn't enough data to rate its revenue and cash flow.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
RDGT PE Valuation
RDGT has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
RDGT Forward outlook
There aren't enough analyst estimates for RDGT to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the stronger earnings trend. Trailing diluted EPS is up 4.9% for NVO versus RDGT down 100%.
RDGT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2021 | -$1,098,000.00 | -$132,750.00 |
| Q4 2020 | -$1,559,250.00 | -1185% |
| Q3 2020 | -$641,250.00 | -$353,025.00 |
| Q2 2020 | -$641,250.00 | -$245,025.00 |
| Q1 2020 | -$965,250.00 | -$839,025.00 |
| Q4 2019 | $143,775.00 | +$3,460,500.00 |
| Q3 2019 | -$288,225.00 | +$3,136,500.00 |
| Q2 2019 | -$396,225.00 | +$2,974,500.00 |
RDGT has returned to profit: it earned $276.00 per share over the past year, after losing money the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the stronger quarterly revenue trend. Revenue is up 2.1% for NVO versus down 8.7% for RDGT.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over RDGT on profitability, with a higher operating margin.
RDGT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $69.4M | -42% |
| Q3 2025 | $62.8M | -12% |
| Q1 2025 | $120M | +58% |
| Q3 2024 | $71.2M | -9.4% |
| Q1 2024 | $76M | -49% |
| Q1 2023 | $148.8M | -9.5% |
| Q1 2022 | $164.4M | +360% |
| Q1 2021 | $35.7M | +18% |
RDGT's revenue has slid since its 2022 peak: $69M last quarter, down 8.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -2.6% | +2.4 points |
| Q3 2025 | -0.1% | -0.5 points |
| Q1 2025 | -0.9% | +13 points |
| Q3 2024 | -3.1% | -1.5 points |
| Q1 2024 | -5% | -3.5 points |
| Q3 2023 | 0.3% | +18 points |
| Q1 2023 | -14% | -9.1 points |
| Q1 2022 | -1.6% | -0.3 points |
RDGT's operating margin was −2.6% last quarter, up 2.4 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the stronger cash trend. Its trailing FCF is down 14% versus its history, compared with RDGT at down 77%.
RDGT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2025 | $1.1M | +$5.3M |
| Q3 2024 | -$10.1M | -1517% |
| Q1 2024 | -$4.2M | -$797.7K |
| Q1 2023 | -$3.4M | +$2.1M |
| Q1 2022 | -$5.5M | -145% |
| Q1 2021 | $12.1M | +219% |
| Q4 2020 | -$12.1M | +$387.3K |
| Q3 2020 | $5M | -44% |
RDGT's free cash flow was −$13M over the past year, against −$9M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over RDGT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
RDGT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.6% | +2.1K shares |
| 1 year | +1048% | +35.6K shares |
| 3 years | +650450% | +39K shares |
| 5 years | +780560% | +39K shares |
| Available history | +1301000% | +39K shares |
RDGT has 39,033 diluted shares, up 1048% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
| Q2 2019 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
RDGT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | -23.5x | Net Cash |
| Q1 2019 | 20.8x | High |
| Q3 2016 | 3.2x | Elevated |
RDGT has more cash than debt.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
RDGT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.8 | Neutral |
| Stochastic | 28.7 | Neutral |
RDGT's weekly RSI is 35 (neutral) and its Stochastic is 29 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RDGT PE vs Healthcare Sector
| Metric | RDGT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RDGT has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
RDGT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.91 | 22% above |
| 20 week MA | $0.99 | 12% above |
| 50 week MA | $122.2 | 99% below |
| 100 week MA | $171.8 | 99% below |
| 200 week MA | $1,289.0 | 100% below |
RDGT has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over RDGT on returns for 2026, with the stronger performance.
RDGT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $66,240.0 | $37,080.0 | -44% |
| 2021 | $37,080.0 | $14,047.6 | -62% |
| 2022 | $14,047.6 | $11,850.0 | -16% |
| 2023 | $11,850.0 | $666.0 | -94% |
| 2024 | $666.0 | $271.5 | -59% |
| 2025 | $271.5 | $483.0 | +78% |
| 2026 YTD | $483.0 | $1.11 | -100% |
RDGT has finished lower in five of the last six years. It's down 100% so far in 2026.